STK11 and non-small cell lung carcinoma: What emerges from NSCLC models mutated in KRAS and STK11/LKB1 is greater sensitivity to phenformin due to both the constitutive activation of KRAS, which induces cell proliferation, and the absence of LKB1 which renders the cell unable to face metabolic stress (63).